RECRUITING

Improving Smoking Abstinence Outcomes in the African American Community Through Extended Treatment

Talk to us

Conditions

Smoking Cessation

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This study will evaluate the efficacy of extended bupropion(6 months) versus standard bupropion treatment (7 weeks) among African American daily smokers.

Official Title

Improving Smoking Abstinence Outcomes in the African American Community Through Extended Treatment

Quick Facts

Study Start:2023-02-28
Study Completion:2026-07-30
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05732272

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * African American
  2. * age \>18 years
  3. * interested in quitting
  4. * smoked \>1 cpd for \>1 years
  5. * smoked on \>25 days in the past month
  6. * willing to take 6 months of study medication and complete all visits
  7. * have a home address and functioning telephone number
  1. * Consistent with contraindications for bupropion:
  2. * use of psychoactive medications
  3. * history of alcohol or substance abuse within the past year
  4. * binge drinking (\>5 drinks on one occasion) \>2 times in the past month
  5. * history of seizures or head trauma; history of bulimia or anorexia nervosa
  6. * pregnant (as measured by over the counter pregnancy test kit for women of child-bearing age only) or contemplating pregnancy; breast feeding
  7. * myocardial infarction in the past 2 months
  8. * reported use of opiates, cocaine, or stimulants
  9. * unstable diabetes
  10. * bupropion is a known inhibitor of the liver enzyme CYP2D6, so those taking drugs known to be higher metabolized by this enzyme (e.g., metoprolol, tamoxifen) will be excluded.
  11. * use of stop smoking medications (bupropion, varenicline, nicotine replacement, fluoxetine, clonidine, buspirone, or doxepin) in the past 30 days
  12. * planning to move from the Kansas City area in the next year
  13. * other smoker in household enrolled in the study.

Contacts and Locations

Study Contact

Tricia Snow, MPH
CONTACT
816-398-8960
psnow@kumc.edu

Principal Investigator

Lisa Sanderson Cox, PhD
PRINCIPAL_INVESTIGATOR
University of Kanas Medical Center

Study Locations (Sites)

University of Kansas Medical Center
Kansas City, Missouri, 64130
United States

Collaborators and Investigators

Sponsor: University of Kansas Medical Center

  • Lisa Sanderson Cox, PhD, PRINCIPAL_INVESTIGATOR, University of Kanas Medical Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-02-28
Study Completion Date2026-07-30

Study Record Updates

Study Start Date2023-02-28
Study Completion Date2026-07-30

Terms related to this study

Additional Relevant MeSH Terms

  • Smoking Cessation